Skip to main content
. 2016 Feb 1;29(Suppl 1):S14–S26. doi: 10.1097/WCO.0000000000000289

FIGURE 1.

FIGURE 1

Strategy for specific therapy in TTR-FAP. CI, contraindications; LT, liver transplantation; TTR-FAP, transthyretin familial amyloid polyneuropathy. aCI for LT include: active and uncontrolled cancer; aged > 50 years for males and > 70 years for females [39▪▪,77], except for Italy (aged >65 years); modified body mass index below 800 kg/m2·g/L; some non-Val30Met TTR mutations; cardiac insufficiency. bStage I: walking unaided outside. cStage II: walking with aid. dProtocol clinical trial for antisense oligonucleotides, small interfering RNA, combination doxycycline–tauroursodeoxycholic acid; or diflunisal off-label. Adapted from [1▪].